Jeffrey S. Heier insider trades
Open-market stock purchases and sales by Jeffrey S. Heier, Chief Scientific Officer at Ocular Therapeutix, Inc, from SEC Form 4 filings since Sep 11, 2015.
Track record: 100% of 1 scored buy are up 5% or more since purchase, averaging +170%.
Recent trades
| Date | Stock | Trade | Value |
|---|---|---|---|
| May 26, 2026 | OCUL Ocular Therapeutix, Inc | Sold | $24.7K |
| Feb 23, 2026 | OCUL Ocular Therapeutix, Inc | Sold | $25.3K |
| Jan 2, 2026 | OCUL Ocular Therapeutix, Inc | Bought (not open market) | — |
| Jan 2, 2026 | OCUL Ocular Therapeutix, Inc | Bought (not open market) | — |
| Nov 24, 2025 | OCUL Ocular Therapeutix, Inc | Sold | $41.8K |
| Oct 2, 2025 | OCUL Ocular Therapeutix, Inc | Sold | $116K |
Companies traded
- OCUL Ocular Therapeutix, Inc: 1 buy, 8 sales, last May 26, 2026